Medication-assisted treatment (MAT) is the most effective treatment for opioid use disorder. Published data consistently shows that MAT reduces overdose deaths by 50–60%, improves treatment retention, decreases illicit opioid use, and improves overall quality of life. Despite this evidence, MAT remains stigmatized — sometimes even within the treatment community itself. Understanding how these medications work, what the evidence shows, and how Colombian programs integrate them is essential for any patient or family considering opioid addiction treatment.
MAT is not "replacing one drug with another." Buprenorphine and methadone are evidence-based medications that normalize brain chemistry, reduce cravings, and prevent withdrawal — allowing patients to engage in the therapeutic work of recovery. Naltrexone blocks opioid effects entirely. All three save lives.
The Three MAT Medications
| Medication | Mechanism | Administration | Key Advantage |
|---|---|---|---|
| Buprenorphine (Suboxone) | Partial opioid agonist — partially activates receptors, reducing cravings and withdrawal | Daily sublingual film/tablet or monthly injection (Sublocade) | Can be prescribed by certified providers; take-home dosing |
| Naltrexone (Vivitrol) | Opioid antagonist — blocks opioid receptors completely | Monthly injection | No abuse potential; eliminates opioid effects if relapse occurs |
| Methadone | Full opioid agonist — fully activates receptors at controlled dose | Daily liquid dose at clinic | Most effective for severe, long-term OUD; highest retention rates |
MAT in Colombian Treatment Programs
Colombian residential programs can initiate buprenorphine (most commonly) or naltrexone during the treatment stay. The critical component is the transition plan: before discharge, the treatment team must coordinate with a US-based MAT provider who will continue the prescription. This handoff is essential — abrupt discontinuation of MAT, especially buprenorphine, resets tolerance and dramatically increases overdose risk if relapse occurs.
Methadone, which requires daily in-person dosing at a certified clinic, is more complex to manage internationally. Most Colombian programs use buprenorphine for opioid MAT initiation due to its flexibility and the availability of monthly injectable formulations (Sublocade) that can bridge the transition home.
Addressing the Stigma
The belief that MAT is "not real recovery" persists in some treatment communities and 12-step groups. This stigma is not supported by evidence and actively harms patients. MAT does not impair cognition or function at therapeutic doses. Patients on MAT can work, drive, parent, and engage fully in life. MAT is recommended by the World Health Organization, NIDA, SAMHSA, and every major medical society. Choosing MAT is a medical decision, not a moral one.
Discuss MAT options with your treatment team without shame or hesitation. If a treatment program tells you that MAT is not "real recovery" or refuses to offer it, that program is not following evidence-based practice. The goal of treatment is sustained recovery and survival — and MAT is the most effective tool we have for opioid use disorder.
Start Your Recovery Journey
Confidential consultation with experienced treatment professionals. No pressure, no judgment — just honest guidance about your options.
Chat Confidentially on WhatsApp